These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19887551)

  • 1. Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.
    Foti C; Florean C; Pezzutto A; Roncaglia P; Tomasella A; Gustincich S; Brancolini C
    Mol Cancer Ther; 2009 Nov; 8(11):3140-50. PubMed ID: 19887551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.
    Fontanini A; Foti C; Potu H; Crivellato E; Maestro R; Bernardi P; Demarchi F; Brancolini C
    J Biol Chem; 2009 Mar; 284(13):8369-81. PubMed ID: 19139105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
    Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
    Demarchi F; Brancolini C
    Drug Resist Updat; 2005 Dec; 8(6):359-68. PubMed ID: 16406769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
    Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.
    Pilchova I; Klacanova K; Dibdiakova K; Saksonova S; Stefanikova A; Vidomanova E; Lichardusova L; Hatok J; Racay P
    Neurochem Res; 2017 Nov; 42(11):3170-3185. PubMed ID: 28725954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
    Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
    Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
    Yu J; Tiwari S; Steiner P; Zhang L
    Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
    Nikiforov MA; Riblett M; Tang WH; Gratchouck V; Zhuang D; Fernandez Y; Verhaegen M; Varambally S; Chinnaiyan AM; Jakubowiak AJ; Soengas MS
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19488-93. PubMed ID: 18042711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
    Laussmann MA; Passante E; Hellwig CT; Tomiczek B; Flanagan L; Prehn JH; Huber HJ; Rehm M
    J Biol Chem; 2012 Apr; 287(18):14402-11. PubMed ID: 22408249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
    Lara PN; Bold RJ; Mack PC; Davies AM; Gumerlock PH; Gandara DR
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S67-71. PubMed ID: 16250931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
    Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
    Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
    Teraishi F; Guo W; Zhang L; Dong F; Davis JJ; Sasazuki T; Shirasawa S; Liu J; Fang B
    Cancer Res; 2006 Jun; 66(12):6072-9. PubMed ID: 16778179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
    Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.